Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10,493 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
RAD21 amplification epigenetically suppresses interferon signaling to promote immune evasion in ovarian cancer.
Deng P, Wang Z, Chen J, Liu S, Yao X, Liu S, Liu L, Yu Z, Huang Y, Xiong Z, Xiao R, Gao J, Liang W, Chen J, Liu H, Hong JH, Chan JY, Guan P, Chen J, Wang Y, Yin J, Li J, Zheng M, Zhang C, Zhou P, Kang T, Teh BT, Yu Q, Zuo Z, Jiang Q, Liu J, Xiong Y, Xia X, Tan J. Deng P, et al. Among authors: yao x. J Clin Invest. 2022 Nov 15;132(22):e159628. doi: 10.1172/JCI159628. J Clin Invest. 2022. PMID: 36201246 Free PMC article.
VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma.
Yao X, Tan J, Lim KJ, Koh J, Ooi WF, Li Z, Huang D, Xing M, Chan YS, Qu JZ, Tay ST, Wijaya G, Lam YN, Hong JH, Lee-Lim AP, Guan P, Ng MSW, He CZ, Lin JS, Nandi T, Qamra A, Xu C, Myint SS, Davies JOJ, Goh JY, Loh G, Tan BC, Rozen SG, Yu Q, Tan IBH, Cheng CWS, Li S, Chang KTE, Tan PH, Silver DL, Lezhava A, Steger G, Hughes JR, Teh BT, Tan P. Yao X, et al. Cancer Discov. 2017 Nov;7(11):1284-1305. doi: 10.1158/2159-8290.CD-17-0375. Epub 2017 Sep 11. Cancer Discov. 2017. PMID: 28893800
Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma.
Nairismägi M-, Gerritsen ME, Li ZM, Wijaya GC, Chia BKH, Laurensia Y, Lim JQ, Yeoh KW, Yao XS, Pang WL, Bisconte A, Hill RJ, Bradshaw JM, Huang D, Song TLL, Ng CCY, Rajasegaran V, Tang T, Tang QQ, Xia XJ, Kang TB, Teh BT, Lim ST, Ong CK, Tan J. Nairismägi M-, et al. Among authors: yao xs. Leukemia. 2018 May;32(5):1147-1156. doi: 10.1038/s41375-017-0004-x. Epub 2018 Feb 2. Leukemia. 2018. PMID: 29434279 Free PMC article.
Genomic and epigenomic EBF1 alterations modulate TERT expression in gastric cancer.
Xing M, Ooi WF, Tan J, Qamra A, Lee PH, Li Z, Xu C, Padmanabhan N, Lim JQ, Guo YA, Yao X, Amit M, Ng LM, Sheng T, Wang J, Huang KK, Anene-Nzelu CG, Ho SWT, Ray M, Ma L, Fazzi G, Lim KJ, Wijaya GC, Zhang S, Nandi T, Yan T, Chang MM, Das K, Isa ZFA, Wu J, Poon PSY, Lam YN, Lin JS, Tay ST, Lee MH, Tan ALK, Ong X, White K, Rozen SG, Beer M, Foo RSY, Grabsch HI, Skanderup AJ, Li S, Teh BT, Tan P. Xing M, et al. Among authors: yao x. J Clin Invest. 2020 Jun 1;130(6):3005-3020. doi: 10.1172/JCI126726. J Clin Invest. 2020. PMID: 32364535 Free PMC article.
Targeting enhancer reprogramming to mitigate MEK inhibitor resistance in preclinical models of advanced ovarian cancer.
Liu S, Zou Q, Chen JP, Yao X, Guan P, Liang W, Deng P, Lai X, Yin J, Chen J, Chen R, Yu Z, Xiao R, Sun Y, Hong JH, Liu H, Lu H, Chen J, Bei JX, Koh J, Chan JY, Wang B, Kang T, Yu Q, Teh BT, Liu J, Xiong Y, Tan J. Liu S, et al. Among authors: yao x. J Clin Invest. 2021 Oct 15;131(20):e145035. doi: 10.1172/JCI145035. J Clin Invest. 2021. PMID: 34464356 Free PMC article.
Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide.
Chen J, Zuo Z, Gao Y, Yao X, Guan P, Wang Y, Li Z, Liu Z, Hong JH, Deng P, Chan JY, Cheah DMZ, Lim J, Chai KXY, Chia BKH, Pang JWL, Koh J, Huang D, He H, Sun Y, Liu L, Liu S, Huang Y, Wang X, You H, Saraf SA, Grigoropoulos NF, Li X, Bei J, Kang T, Lim ST, Teh BT, Huang H, Ong CK, Tan J. Chen J, et al. Among authors: yao x. Clin Epigenetics. 2023 Feb 6;15(1):19. doi: 10.1186/s13148-023-01436-6. Clin Epigenetics. 2023. PMID: 36740715 Free PMC article. Clinical Trial.
PBRM1-deficient PBAF complexes target aberrant genomic loci to activate the NF-κB pathway in clear cell renal cell carcinoma.
Yao X, Hong JH, Nargund AM, Ng MSW, Heng HL, Li Z, Guan P, Sugiura M, Chu PL, Wang LC, Ye X, Qu J, Kwek XY, Lim JCT, Ooi WF, Koh J, Wang Z, Pan YF, Ong YS, Tan KY, Goh JY, Ng SR, Pignata L, Huang D, Lezhava A, Tay ST, Lee M, Yeo XH, Tam WL, Rha SY, Li S, Guccione E, Futreal A, Tan J, Yeong JPS, Hong W, Yauch R, Chang KT, Sobota RM, Tan P, Teh BT. Yao X, et al. Nat Cell Biol. 2023 May;25(5):765-777. doi: 10.1038/s41556-023-01122-y. Epub 2023 Apr 24. Nat Cell Biol. 2023. PMID: 37095322
Integrative multiomics enhancer activity profiling identifies therapeutic vulnerabilities in cholangiocarcinoma of different etiologies.
Hong JH, Yong CH, Heng HL, Chan JY, Lau MC, Chen J, Lee JY, Lim AH, Li Z, Guan P, Chu PL, Boot A, Ng SR, Yao X, Wee FYT, Lim JCT, Liu W, Wang P, Xiao R, Zeng X, Sun Y, Koh J, Kwek XY, Ng CCY, Klanrit P, Zhang Y, Lai J, Tai DWM, Pairojkul C, Dima S, Popescu I, Hsieh SY, Yu MC, Yeong J, Kongpetch S, Jusakul A, Loilome W, Tan P, Tan J, Teh BT. Hong JH, et al. Among authors: yao x. Gut. 2024 May 10;73(6):966-984. doi: 10.1136/gutjnl-2023-330483. Gut. 2024. PMID: 38050079
10,493 results
You have reached the last available page of results. Please see the User Guide for more information.